TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Study to Examine the Effectiveness of Progesterone in Preventing Severe Preterm Delivery
Brief Summary: The aim of our study is to evaluate the effect of use of prophylactic vaginal progesterone on the incidence of severe preterm delivery, defined as delivery before 33+6 weeks in women with a short cervical length of 15mm.


Options:
A: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
B: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Study to Examine the Effectiveness of Progesterone in Preventing Severe Preterm Delivery
Brief Summary: The aim of our study is to evaluate the effect of use of prophylactic vaginal progesterone on the incidence of severe preterm delivery, defined as delivery before 33+6 weeks in women with a short cervical length of 15mm.


Options:
A: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 17-alpha hydroxyprogesterone caproate, Makena®; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17-alpha-hydroxy-progesterone caproate, Makena® | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Castor Oil (Placebo) | Intervention Type: DRUG; Name: 17-alpha-hydroxy-progesterone caproate, Makena®; Assigned to Arm(s): 17-alpha hydroxyprogesterone caproate, Makena® | Intervention Type: DRUG; Name: Castor Oil (Placebo); Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI)
Brief Summary: The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction


Options:
A: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
B: Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): N/A
C: Arm Label: EPO group; Type: EXPERIMENTAL; Interventions: Drug: EPO group | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: EPO group; Assigned to Arm(s): EPO group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)
Brief Summary: The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban compares with enoxaparin in preventing these clots. The safety of apixaban will also be studied


Options:
A: Arm Label: Apixaban, 2.5 mg BID plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban, Drug: Enoxaparin-matching placebo | Arm Label: Enoxaparin, 40 mg QD plus placebo; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin, Drug: Apixaban-matching placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin, 40 mg QD plus placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban, 2.5 mg BID plus placebo | Intervention Type: DRUG; Name: Enoxaparin-matching placebo; Assigned to Arm(s): Apixaban, 2.5 mg BID plus placebo | Intervention Type: DRUG; Name: Apixaban-matching placebo; Assigned to Arm(s): Enoxaparin, 40 mg QD plus placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate
D: Intervention Type: PROCEDURE; Name: Bilateral ultrasound examination 7+/- 2 after surgery; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy.
Brief Summary: Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.


Options:
A: Arm Label: Arm I (cabozantinib-s-malate); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (sunitinib malate); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Sunitinib Malate | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (sunitinib malate) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm II (sunitinib malate)
B: Arm Label: Avelumab in combination with axitinib; Type: EXPERIMENTAL; Interventions: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736) | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Avelumab (MSB0010718C); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy.
Brief Summary: Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.


Options:
A: Arm Label: Sorafenib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib+Pazopanib | Arm Label: Pazopanib followed by Sorafenib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib+Sorafenib | Intervention Type: DRUG; Name: Sorafenib+Pazopanib; Assigned to Arm(s): Sorafenib followed by pazopanib | Intervention Type: DRUG; Name: Pazopanib+Sorafenib; Assigned to Arm(s): Pazopanib followed by Sorafenib
B: Arm Label: Cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib tablets | Arm Label: Everolimus (Afinitor); Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus (Afinitor) tablets | Intervention Type: DRUG; Name: Cabozantinib tablets; Assigned to Arm(s): Cabozantinib (XL184) | Intervention Type: DRUG; Name: Everolimus (Afinitor) tablets; Assigned to Arm(s): Everolimus (Afinitor)
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
D: Arm Label: Axitinib; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Axitinib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)
Brief Summary: The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.


Options:
A: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: ceftaroline, Drug: Placebo | Arm Label: IV Vancomycin plus IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: vancomycin plus aztreonam | Intervention Type: DRUG; Name: ceftaroline; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: vancomycin plus aztreonam; Assigned to Arm(s): IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ceftaroline fosamil for Injection
B: Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Arm Label: CEM-102 Regimen A; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Arm Label: CEM-102 Regimen B; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen A | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen B
C: Arm Label: Ceftaroline for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline | Arm Label: IV Vancomycin and IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: IV Vancomycin plus IV Aztreonam; Assigned to Arm(s): IV Vancomycin and IV Aztreonam | Intervention Type: DRUG; Name: Ceftaroline; Assigned to Arm(s): Ceftaroline for Injection
D: Intervention Type: DRUG; Name: MK0826, ertapenem sodium / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Brief Summary: The goal of this clinical research study is to learn whether being hydrated (given liquids) through a catheter in a vein or in the tissue under the skin can improve symptoms of dehydration.

Objectives:

1.1 Determine whether parenteral hydration is superior to placebo in improving symptoms associated with dehydration (such as fatigue, myoclonus, sedation, and hallucinations) in advanced cancer patients receiving hospice care.

1.2 Determine whether parenteral hydration is superior to placebo in delaying the onset or reducing the severity of delirium in patients with advanced cancer receiving hospice care.

1.3 Describe the meaning patients and primary caregivers attribute to dehydration and re-hydration at the end of patient's lives.


Options:
A: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2
B: Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dementia Care Management (DCM); Type: EXPERIMENTAL; Interventions: Behavioral: Dementia Care Management (DCM) | Intervention Type: BEHAVIORAL; Name: Dementia Care Management (DCM); Assigned to Arm(s): Dementia Care Management (DCM)
C: Arm Label: Hydration: Normal Saline (salt water); Type: EXPERIMENTAL; Interventions: Drug: Saline | Arm Label: Placebo: Lower Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Hydration: Normal Saline (salt water) | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo: Lower Saline
D: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: a modified NTU-HELP | Intervention Type: BEHAVIORAL; Name: a modified NTU-HELP; Assigned to Arm(s): Experimental Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Brief Summary: The goal of this clinical research study is to learn whether being hydrated (given liquids) through a catheter in a vein or in the tissue under the skin can improve symptoms of dehydration.

Objectives:

1.1 Determine whether parenteral hydration is superior to placebo in improving symptoms associated with dehydration (such as fatigue, myoclonus, sedation, and hallucinations) in advanced cancer patients receiving hospice care.

1.2 Determine whether parenteral hydration is superior to placebo in delaying the onset or reducing the severity of delirium in patients with advanced cancer receiving hospice care.

1.3 Describe the meaning patients and primary caregivers attribute to dehydration and re-hydration at the end of patient's lives.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard non-pharmacological prevention intervention | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Occupational therapy intervention, Behavioral: Standard non-pharmacological prevention intervention | Intervention Type: BEHAVIORAL; Name: Occupational therapy intervention; Assigned to Arm(s): Treatment | Intervention Type: BEHAVIORAL; Name: Standard non-pharmacological prevention intervention; Assigned to Arm(s): Control, Treatment
B: Arm Label: Non-Clinically Assisted Hydration arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-Clinically Assisted Hydration arm | Arm Label: Clinically Assisted Hydration arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinically Assisted Hydration arm | Intervention Type: OTHER; Name: Non-Clinically Assisted Hydration arm; Assigned to Arm(s): Non-Clinically Assisted Hydration arm | Intervention Type: OTHER; Name: Clinically Assisted Hydration arm; Assigned to Arm(s): Clinically Assisted Hydration arm
C: Arm Label: Hydration: Normal Saline (salt water); Type: EXPERIMENTAL; Interventions: Drug: Saline | Arm Label: Placebo: Lower Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Hydration: Normal Saline (salt water) | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo: Lower Saline
D: Arm Label: CPAP therapy arm; Type: EXPERIMENTAL; Interventions: Other: CPAP treatment | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CPAP treatment; Assigned to Arm(s): CPAP therapy arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers
Brief Summary: A Phase I study of the Safety and immunogenicity of MVA85A in healthy Gambian volunteers


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: BCG | Intervention Type: BIOLOGICAL; Name: BCG; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Intervention Type: BIOLOGICAL; Name: MVA 85A; Assigned to Arm(s): 1, 2, 3, 4
C: Intervention Type: BIOLOGICAL; Name: MVA85A (Tuberculosis vaccine); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: FP85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: FP85A, Biological: MVA85A | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: FP85A, Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: FP85A; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 2, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated With Medium Doses of Inhaled Glucocorticosteroids
Brief Summary: This study is being conducted to demonstrate the non-inferiority between two inhaled glucocorticosteroids and long-acting bronchodilator combination drugs called mometasone furoate/formoterol fumarate in a metered-dose inhaler (MDI) and fluticasone propionate/salmeterol in a dry powder inhaler (DPI) on lung function. Information on the onset of action, the overall safety, and how the drugs control asthma will also be assessed. The study is approximately 1 year in duration.


Options:
A: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone plus formoterol fixed combination | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone plus salmeterol fixed combination | Intervention Type: DRUG; Name: Beclomethasone plus formoterol fixed combination; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone plus salmeterol fixed combination; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection
Brief Summary: The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.


Options:
A: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039) | Arm Label: PIP/TAZ-AMC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid | Intervention Type: DRUG; Name: Moxifloxacin (Avelox, BAY12-8039); Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid; Assigned to Arm(s): PIP/TAZ-AMC
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Intervention Type: DRUG; Name: oritavancin; Assigned to Arm(s): 1, 2, 3
C: Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo group | Arm Label: antibiotic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-sulfamethoxazole | Intervention Type: DRUG; Name: Trimethoprim-sulfamethoxazole; Assigned to Arm(s): antibiotic group | Intervention Type: DRUG; Name: Placebo group; Assigned to Arm(s): placebo group
D: Arm Label: Ceftaroline for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline | Arm Label: IV Vancomycin and IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: IV Vancomycin plus IV Aztreonam; Assigned to Arm(s): IV Vancomycin and IV Aztreonam | Intervention Type: DRUG; Name: Ceftaroline; Assigned to Arm(s): Ceftaroline for Injection

Answer: D